In 1Q16, LabCorp’s (LH) national clinical laboratory business, LabCorp Diagnostics, accounted for 69.3% of the company’s total revenues. Despite facing the impact of about -0.6% in revenues on a ...
Hosted on MSN
LH Q3 Deep Dive: Labcorp Sees Diagnostic Growth, Eyes Specialty Testing and Efficiency Initiatives
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus ...
The 2025 guidance anticipates Diagnostics revenue growth of 6.5% to 7.7%, driven equally by organic growth and the annualization of 2024 acquisitions. Biopharma revenue is forecasted to grow 3% to 5%, ...
CEO Adam Schechter highlighted a 5% revenue growth for Q1 2025, with Diagnostics Laboratories achieving a 6% increase. This growth was attributed to rebounding volumes and strong managed care access.
TOLEDO - NAMSA, a medical device testing and regulatory consulting firm, has acquired Labcorp’s (NYSE:LH) Early Development medical device testing business, according to a press release issued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback